Skeletal responses to romosozumab after 12 months of denosumab

ABSTRACT Romosozumab, a monoclonal anti‐sclerostin antibody that has the dual effect of increasing bone formation and decreasing bone resorption, reduces fracture risk within 12 months. In a post hoc, exploratory analysis, we evaluated the effects of romosozumab after 12 months of denosumab in postm...

Full description

Bibliographic Details
Published in:JBMR Plus
Main Authors: Michael R. McClung, Michael A. Bolognese, Jacques P. Brown, Jean‐Yves Reginster, Bente L. Langdahl, Yifei Shi, Jen Timoshanko, Cesar Libanati, Arkadi Chines, Mary K. Oates
Format: Article
Language:English
Published: Oxford University Press 2021-07-01
Subjects:
ANABOLIC
ANTIRESORPTIVE
DENOSUMAB
ROMOSOZUMAB
TREATMENT SEQUENCE
Online Access:https://doi.org/10.1002/jbm4.10512

Internet

https://doi.org/10.1002/jbm4.10512

Similar Items